Vanda Pharmaceuticals Inc.
VNDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001347178
No open-market purchases or sales by Vanda Pharmaceuticals Inc. insiders were filed in the last 90 days; 172 institutions reported holding it in 13F filings for Q2 2026, worth $304.1M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Vanda Pharmaceuticals Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 146 | 140 | −6 |
| Shares | 44.0M | 45.0M | +963.2K (+2.2%) |
| Value | $202.1M | $212.4M | +$10.2M (+5.1%) |
New holders (21)
Institutions that held Vanda Pharmaceuticals Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna Portfolio Strategies, LLC | 97,059 | $458.1K | 0.01% |
| Simplex Trading, LLC | 62,316 | $294.0K | 0.01% |
| StoneX Group Inc. | 20,000 | $94.4K | 0.00% |
| UBS Asset Management Americas Inc | 17,565 | $82.9K | 0.00% |
| R Squared Ltd | 17,556 | $82.9K | 0.05% |
| EntryPoint Capital, LLC | 17,520 | $82.7K | 0.04% |
| Engineers Gate Manager LP | 15,806 | $74.6K | 0.00% |
| Cerity Partners LLC | 14,668 | $69.2K | 0.00% |
| Wolverine Trading, LLC | 11,417 | $54.6K | 0.00% |
| Ieq Capital, LLC | 11,369 | $53.7K | 0.00% |
| Caitong International Asset Management Co., Ltd | 664 | $3.13K | 0.00% |
| SRS Capital Advisors, Inc. | 621 | $2.93K | 0.00% |
| Group One Trading, L.P. | 555 | $2.62K | 0.00% |
| Clearstead Advisors, LLC | 472 | $2.23K | 0.00% |
| Essential Partners LLC | 467 | $2.20K | 0.00% |
| Rothschild Investment LLC | 250 | $1.18K | 0.00% |
| Fifth Third Bancorp | 153 | $722 | 0.00% |
| EverSource Wealth Advisors, LLC | 110 | $519 | 0.00% |
| Hughes Financial Services, LLC | 121 | $511 | 0.00% |
| GAMMA Investing LLC | 63 | $297 | 0.00% |
| Covestor Ltd | 29 | $0 | 0.00% |
Sold out (27)
Institutions that held Vanda Pharmaceuticals Inc. at the end of Q1 2025 and filed for Q2 2025 without it.